BRIDGEWATER, N.J., Jan. 25, 2011 /PRNewswire/ -- Aerocrine, Inc., an innovative medical technology company focused on the treatment of patients with inflamed airways, has selected R&J Public Relations, LLC of Bridgewater, N.J., as its public relations agency of record. R&J will conduct strategic public relations for the Aerocrine brand; most immediately surrounding the NIOX MINO®, the first and only hand-held device available to measure exhaled nitric oxide (eNO) to aid in asthma management in the United States.
For the first time ever, The NIOX MINO provides doctors the ability to more effectively diagnose, monitor and optimize therapy for individuals suffering from inflammatory airway diseases through one easy-to-use device. This ground-breaking technology helps eliminate the uncertainties that contribute to asthma morbidity and mortality, including incorrect diagnosis, patient adherence issues, and identifying those patients that will be responsive to treatment.
"Our comprehensive experience and strong presence in the healthcare market space combined with our aggressive and proactive consumer and media relations practices will provide Aerocrine with the leverage they need to elevate their innovative brand and products," said Scott Marioni, Executive Vice President of R&J Public Relations. "R&J is confident that our strategic public relations will significantly increase the awareness of the Aerocrine brand and NIOX MINO while positioning eNO testing as a standard for patients with asthmatic symptoms."
The founders of Aerocrine originated from the Karolinska Institute in Sweden where they first discovered the significant tie between nitric oxide (NO) and inflammation. Aerocrine used this discovery as a basis for creating products that assist in the management and care of people afflicted with varying airway inflammatory diseases.
R&J's main objective is to promptly elevate Aero